SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-080089
Filing Date
2021-06-11
Accepted
2021-06-11 16:01:48
Documents
17
Period of Report
2021-06-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2119092d3_8k.htm   iXBRL 8-K 33892
2 EXHIBIT 1.1 tm2119092d3_ex1-1.htm EX-1.1 268754
3 EXHIBIT 5.1 tm2119092d3_ex5-1.htm EX-5.1 10156
4 EXHIBIT 99.1 tm2119092d3_ex99-1.htm EX-99.1 7919
5 EXHIBIT 99.2 tm2119092d3_ex99-2.htm EX-99.2 8095
9 GRAPHIC tm2119092d3_ex5-1img0011.jpg GRAPHIC 5240
  Complete submission text file 0001104659-21-080089.txt   589397

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA acrs-20210608.xsd EX-101.SCH 3190
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrs-20210608_lab.xml EX-101.LAB 34592
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrs-20210608_pre.xml EX-101.PRE 22713
10 EXTRACTED XBRL INSTANCE DOCUMENT tm2119092d3_8k_htm.xml XML 3595
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 211011222
SIC: 2834 Pharmaceutical Preparations